Temafloxacin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Temafloxacin
Temafloxacin.png
Systematic (IUPAC) name
1-(2,4-Difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
Clinical data
Legal status
  • Withdrawn
Routes Oral
Identifiers
ATC code J01MA05
PubChem CID 60021
DrugBank DB01405
ChemSpider 54143 YesY
UNII 1WZ12GTT67 N
KEGG D02469 N
ChEBI CHEBI:77788 N
ChEMBL CHEMBL277100 YesY
Chemical data
Formula C21H18F3N3O3 
Mol. mass 417.381 g/mol
 N (what is this?)  (verify)

Temafloxacin (marketed by Abbott Laboratories as Omniflox) is a fluoroquinolone antibiotic drug which was withdrawn from sale in the United States shortly after its approval in 1992 because of serious adverse effects resulting in three deaths.[citation needed]

Omniflox was approved to treat lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections in the United States by the Food and Drug Administration in January 1992. Severe adverse reactions, including allergic reactions and hemolytic anemia,[1] developed in about fifty patients during the first four months of its use, leading to three patient deaths. Abbott withdrew the drug from sale in June 1992.

See also[edit]

References[edit]

  1. ^ Rubinstein, E. (2001). "History of quinolones and their side effects.". Chemotherapy. 47 Suppl 3: 3–8; discussion 44–8. doi:10.1159/000057838. PMID 11549783. 

External links[edit]